Who are Aurion Biotech's investors?

Aurion Biotech's investors include Visionary Ventures, Deerfield Management Company, Flying L Partners.

How much funding has Aurion Biotech raised?

Aurion Biotech has disclosed $81.4M raised across 3 rounds.

Where is Aurion Biotech headquartered?

Aurion Biotech is headquartered in Seattle, US.

Aurion Biotech

Seattle, US · Founded 2021 · Delaware corporation · 116 employees on LinkedIn · 3 known investors

Find your way into Aurion Biotech

34 people in our graph share verified history with the Aurion Biotech team — schools, employers, funds. One of them is your warm intro.

Mike Fitzgeraldunlockedknows DAVID ROSTOV · together at LogicGate (overlapped)

×8knows the team · via Avalara

×2knows the team · via LogicGate

knows the team · via Identity

Aurion Biotech develops regenerative cell therapies for ophthalmology, focused on treating blindness and vision loss from corneal endothelial disease. Its lead program, AURN001, is a combination therapy made from human donor endothelial cells intended to restore corneal clarity as an alternative to donor corneal transplantation.

Biotech Healthtech Medical Devices

Founders & leadership

DAVID ROSTOV inChief Financial Officer2021–2024David Rostov is an executive at Aurion Biotech, a company developing regenerative cell therapies for corneal diseases. He brings experience in finance leadership, mergers and acquisitions, and fundraising across biotech and technology companies, with prior involvement in public and private board roles.

GREG KUNSTNamed on SEC filing

PATRICK LALLYNamed on SEC filing

JEANNETTE BANKESNamed on SEC filing

CHRISTINE MCCAULEYNamed on SEC filing

ARNAUD LACOSTENamed on SEC filing

TOM FRINZINamed on SEC filing

Board

LINK WILLIAMBoard director

ANDREW ELBARDISSI in 𝕏Board MemberPartner at Deerfield Management Company

Investors · 3

Visionary VenturesNewport Beach · $5M – $15M

Deerfield Management Companyreported · 2 sourcesNew Yorkvia Andrew ElBardissi · board

Flying L Partnersreported · 2 sources

Reported raises · per SEC filings

Form D private placements

$81.4M disclosed across 3 rounds · 2022

▶$26.1MraisedApr 2022 · 2 investors · Biotechnology

Rule 506(c)

Officers, directors & promoters on the filing

JEANNETTE BANKESDirector
LINK WILLIAMDirector
GREG KUNSTExecutive Officer, Director
PATRICK LALLYDirector
ANDREW ELBARDISSIDirector
ARNAUD LACOSTEExecutive Officer
CHRISTINE MCCAULEYDirector
DAVID ROSTOVExecutive Officer
TOM FRINZIDirector

Offering amount: $26.1M
Amount sold: $26.1M
First sale: Apr 2022
Incorporated: Corporation, Delaware, 2021
Federal exemptions: 06c

Full filing on SEC EDGAR ↗

▶$11KraisedApr 2022 · 32 investors · Biotechnology

Rule 506(c)

Officers, directors & promoters on the filing

GREG KUNSTExecutive Officer, Director
PATRICK LALLYDirector
JEANNETTE BANKESDirector
LINK WILLIAMDirector
DAVID ROSTOVExecutive Officer
ANDREW ELBARDISSIDirector
CHRISTINE MCCAULEYDirector
ARNAUD LACOSTEExecutive Officer
TOM FRINZIDirector

Offering amount: $11K
Amount sold: $11K
First sale: Apr 2022
Incorporated: Corporation, Delaware, 2021
Federal exemptions: 06c

Full filing on SEC EDGAR ↗

▶$55.3MraisedApr 2022 · 9 investors · Biotechnology

Rule 506(c)

Officers, directors & promoters on the filing

JEANNETTE BANKESDirector
LINK WILLIAMDirector
ANDREW ELBARDISSIDirector
PATRICK LALLYDirector
GREG KUNSTExecutive Officer, Director
CHRISTINE MCCAULEYDirector
DAVID ROSTOVExecutive Officer
ARNAUD LACOSTEExecutive Officer
TOM FRINZIDirector

Offering amount: $120.3M
Amount sold: $55.3M
Sales commissions: $4M
Placement agents: Raymond James
First sale: Apr 2022
Incorporated: Corporation, Delaware, 2021
Federal exemptions: 06c

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap

Aro Biotherapeutics29 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.

virion17 shared keywordsVirion Therapeutics develops CD8+ T cell-based immunotherapies using genetically encoded checkpoint modifiers delivered with target-specific antigens via a viral vector platform, targeting cancers and chronic infectious diseases. Its lead product, VRON-0200, is in clinical development as a potential functional cure for chronic hepatitis B.

Companies competing with Aurion Biotech for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Cell therapy weekly: FDA approves glycogen storage disease type 1a gene therapyregmednet.com · Aug 2026

Aurion Biotech Raises $120M in Funding - FinSMEsfinsmes.com · Apr 2022

AURION BIOTECH RAISES $120 MILLION FROM DEERFIELD, PETRICHOR, FLYING L PARTNERS, FALCON VISION/KKR AND VISIONARY VENTURES - Aurion Biotech %aurionbiotech.com · Apr 2022

Frequently asked questions

What does Aurion Biotech do?: Aurion Biotech develops regenerative cell therapies for ophthalmology, focused on treating blindness and vision loss from corneal endothelial disease. Its lead program, AURN001, is a combination therapy made from human donor endothelial cells intended to restore corneal clarity as an alternative to donor corneal transplantation.
Who are Aurion Biotech's investors?: Aurion Biotech's investors include Visionary Ventures, Deerfield Management Company, Flying L Partners.
How much funding has Aurion Biotech raised?: Aurion Biotech has disclosed $81.4M raised across 3 rounds.
Where is Aurion Biotech headquartered?: Aurion Biotech is headquartered in Seattle, US.